Drug Trial News

RSS

Anakinra shows promise in reducing symptoms in patients with Sanfilippo syndrome

As a neurodegenerative disease characterized by childhood onset dementia, Sanfilippo syndrome causes immense suffering in many ways, including pain, loss of speech, extreme agitation, and distress, gastrointestinal symptoms, and profound sleep disturbance.

21 Jun 2024

Repurposing anti-retroviral medications for brain tumor treatment: The RETREAT trial

Drugs developed to combat HIV and AIDS are being trialed for the first time in patients with multiple brain tumors.

21 Jun 2024

Study: Anti-inflammatory drug celecoxib benefits PIK3CA-mutated colon cancer patients

An analysis of data from a randomized clinical trial for patients with stage 3 colon cancer found that those with PIK3CA mutations who took celecoxib, an anti-inflammatory drug, after surgery lived significantly longer and had longer disease-free survival compared to those without the mutation.

18 Jun 2024

Nicotinamide riboside boosts walking endurance in peripheral artery disease

The over-the-counter supplement nicotinamide riboside, a form of vitamin B3, increased the walking endurance of patients with peripheral artery disease, a chronic leg condition for which there are few effective treatments.

18 Jun 2024

Global study confirms pantoprazole's role in reducing upper GI bleeding in the ICU

A widely available drug helps prevent upper gastrointestinal bleeding in critically ill adults on a breathing machine, according to the results of a global study and meta-analysis led by researchers at McMaster University.

14 Jun 2024

MEK inhibitor trametinib shows potential in pediatric JMML treatment

The MEK inhibitor trametinib (Mekinist) was an effective treatment for pediatric patients with relapsed or refractory juvenile myelomonocytic leukemia (JMML) enrolled in a phase II clinical trial, with seven of 10 patients alive after a median of two years.

13 Jun 2024

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

12 Jun 2024

Crinecerfont: A promising compound for reducing corticosteroid dependence in CAH patients

People born with the common form of congenital adrenal hyperplasia lack an enzyme in the adrenal glands needed to make the hormones cortisol and aldorsterone, which are involved in the body's response to stress and blood pressure regulation.

10 Jun 2024

Clinical trial demonstrates efficacy of two-drug therapy for methamphetamine addiction

A clinical trial on a two-drug therapy for methamphetamine use disorder reduced use of the highly addictive drug for up to 12 weeks after initiation of treatment, UCLA-led research suggests.

10 Jun 2024

Stanford study finds 15-day paxlovid treatment safe but ineffective for long COVID

In a clinical trial conducted by Stanford Medicine investigators and their colleagues, a 15-day course of Paxlovid - an antiviral drug combination targeting SARS-CoV-2, the virus that causes COVID-19 - proved safe as an extended-duration treatment but didn't lessen select symptoms of the syndrome known as long COVID: the persistence, or reappearance, of COVID-related symptoms three months or more after an initial COVID-19 infection.

7 Jun 2024

New hope for BCG-unresponsive bladder cancer patients with innovative combination therapy

In a groundbreaking advance that could revolutionize bladder cancer treatment, a novel combination of cretostimogene grenadenorepvec and pembrolizumab has shown remarkable efficacy in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.

6 Jun 2024

Phase III trial highlights benefits of intensity modulated proton therapy for oropharyngeal cancer

According to preliminary data from a multi-institution Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, intensity modulated proton therapy (IMPT) achieved similar clinical outcomes and offered significant patient benefits when compared to traditional intensity modulated radiation therapy (IMRT) as part of chemoradiation treatment for patients with oropharyngeal (head and neck) cancer.

6 Jun 2024

New bilateral gene therapy shows promising results in treating genetic hearing loss

A novel gene therapy designed to target a form of inherited deafness restored hearing function in five children who were treated in both ears.

5 Jun 2024

Novel combination treatment outperforms standard therapy in patients with EGFR NSCLC

The combination of the antibody amivantamab and lazertinib, a drug targeting EGFR, shows better clinical benefits compared to standard treatment in patients with advanced or metastatic non-small cell lung cancer with EGFR gene mutations who also present one of these poor prognosti markers: brain and/or liver metastases, p53 gene co-mutations, or the presence of circulating tumor DNA.

4 Jun 2024

SU2C-SARC032 trial: Immunotherapy reduces relapse risk in soft tissue sarcoma by 43%

For the last three decades, breakthroughs have been sparse for soft tissue sarcomas, which are rare cancers that affect muscles, fat and other connective tissues.

4 Jun 2024

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

Clinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).

3 Jun 2024

RNA-based therapy shows promise in reducing cholesterol and triglycerides

A small interfering RNA (siRNA) investigational therapy that inhibits a gene involved in lipoprotein metabolism has been shown in a clinical trial led by Mount Sinai researchers to significantly reduce levels of different types of cholesterol and triglycerides in individuals with mixed hyperlipidemia, a condition in which fats build up in the blood.

29 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

SELECT trial shows semaglutide reduces kidney decline in obese patients

The SELECT Trial has revealed the potential of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in combating kidney function decline among individuals with overweight or obesity and established cardiovascular disease but without diabetes.

25 May 2024

Immunotherapy-chemotherapy combo boosts survival for patients with metastatic colorectal cancer

A study led by UCLA Health Jonsson Comprehensive Cancer Center researchers found that using a combination of experimental immunotherapy drugs with chemotherapy significantly improves progression-free survival and overall survival for patients with metastatic colorectal cancer who have previously undergone standard chemotherapy treatment when compared to those who received the targeted therapy regorafenib alone.

24 May 2024

Previous
1
...
24
25
26
27
28
29
30
...
1162
Next